Search Results - "Keer, H.N"

381 Preliminary results of a dose escalation study of the Fibroblast Growth Factor (FGF) “trap” FP-1039 (FGFR1:Fc) in patients with advanced malignancies by Tolcher, A, Papadopolous, K, Patniak, A, Heath, E, Weise, A, Prokop, T, Morrone, S, Zanghi, J, Keer, H.N, LoRusso, P

Get full text

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors by Tolcher, A.W., Papadopoulos, K.P., Patnaik, A., Wilson, K., Thayer, S., Zanghi, J., Gemo, A.T., Kavanaugh, W.M., Keer, H.N., LoRusso, P.M.

“…Fibroblast growth factors (FGFs) play important roles in multiple cancers by supporting tumor growth and angiogenesis. FP-1039 (GSK3052230) is a FGF ligand…”
Get full text

123P A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: The run-in phase of the NIBIT Foundation ML1 study by Di Giacomo, A.M., Rossi, G., Calabro, L., Pascucci, A., Vegni, V., Simonetti, E., Colucci, M., Valente, M., Gibilisco, G., Frongia, F., Lofiego, M.F., Amato, G., Keer, H.N., Oganesian, A., Chan, D., Giannarelli, D., Ceccarelli, M., Anichini, A., Covre, A., Maio, M.

Get full text